EGFR and non-small cell lung carcinoma: Whether the latter could be meaningful for NSCLC is still in its infancy, but it could be promising that synthetic lethality is described between CDK12 inhibition and EGFR tyrosine kinase inhibitors, since EGFR deregulation is a recurrently observed cancer-driving event in NSCLC [1,63,64].